DAIICHI SANKYO CO LTD

Explore Daiichi Sankyo’s dual focus: Ifinatamab deruxtecan’s breakthrough ADC potential vs. Fortis Healthcare litigation risk, and what it means for investors.

Supreme Court orders independent forensic audit of Daiichi Sankyo, ensuring corporate transparency while keeping clinical trials, safety data and patient care unchanged.

North TK Venture appeals Tokyo court ruling, citing Dai Sankyo delays that hurt IHH Healthcare’s Fortis acquisition—impacting cross‑border healthcare M&A risk.

Enhertu’s CHMP recommendation marks a new era for adjuvant HER2‑positive breast cancer, as Daiichi Sankyo & AstraZeneca launch the oncology therapy worldwide.

New approvals for Daiichi Sankyo’s Enhertu and Datroway expand its ADC reach in breast cancer, boosting its competitive edge and global oncology impact.

Explore how AstraZeneca’s oncology portfolio blends high‑impact hits like ENHERTU and TAGRISSO with strategic challenges in Etcamah, shaping future M&A and market access tactics.

DAIICHI SANKYO’s Phase II radiotherapy trial for a rare blood disorder shows 57% response, 28% complete response, and strong safety—paving the way for accelerated approval and new oncology drugs.

Forensic audit of Fortis‑IHH share deals: Delhi High Court probes, but IHH’s solid cash flow and 51%‑target strategy stay on track, keeping analysts bullish.

New real‑world evidence shows bempedoic acid cuts LDL‑C by up to 38 mg/dL and can secure value‑based pricing in Europe, boosting outcomes while lowering costs.

How Daiichi Sankyo’s 0.8% stock uptick reflects new oncology candidates, a Singapore research hub, and U.S. partnership, boosting earnings and investor confidence.